These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8635869)

  • 21. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
    Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
    Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
    Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
    Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
    Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
    Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
    Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
    Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
    Wawrzynczak EJ; Derbyshire EJ; Henry RV; Parnell GD; Smith A; Waibel R; Stahel RA
    Br J Cancer; 1990 Sep; 62(3):410-4. PubMed ID: 2169852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
    Tsai LK; Pop LM; Liu X; Vitetta ES
    Toxins (Basel); 2011 Apr; 3(4):409-19. PubMed ID: 22069716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
    Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
    J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
    Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P
    Int J Cancer; 1995 Oct; 63(2):304-9. PubMed ID: 7591221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.
    Derbyshire EJ; Henry RV; Stahel RA; Wawrzynczak EJ
    Br J Cancer; 1992 Sep; 66(3):444-51. PubMed ID: 1325825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
    Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
    Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1994 Aug; 84(3):702-7. PubMed ID: 7519071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
    Van Horssen PJ; Preijers FW; Van Oosterhout YV; Eling WM; De Witte T
    Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
    Myers DE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
    Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
    Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.